Study to Evaluate Delta-HLD Technology for Detecting Colorectal Cancer in Adults Aged 45 to 75

What this Trial Is About

Researchers are studying colorectal cancer detection using Epiliquids delta-HLD technology, a new liquid biopsy method that identifies tumor-specific methylation biomarkers. This proof-of-concept observational case-control study includes participants with confirmed colorectal adenocarcinoma and those with negative colonoscopy results. The study aims to assess the sensitivity, specificity, and agreement of delta-HLD biomarker detection in blood and tissue samples, validating its potential as a minimally invasive diagnostic tool. The study collects blood plasma and tumor tissue samples from two groups individuals diagnosed with colorectal cancer and individuals showing no cancer signs through colonoscopy. Delta-HLD technology uses sequential enzymatic pre-treatment combined with PCR to sensitively and multiplexedly detect colorectal cancer biomarkers. Participants are grouped as cases or controls based on their diagnosis. No treatments are administered as this is an observational study. Participants will provide blood andor tissue samples prior to any treatment or surgery. Researchers will analyze these samples to measure how accurately delta-HLD detects colorectal cancer biomarkers. The primary outcome is the sensitivity and specificity of delta-HLD within three months after sample collection. The study runs until December 2026 and involves adults aged 45 to 75 years. No interventions or therapies are applied during the study.

Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD